



## State of Oklahoma **SoonerCare**

## Sarclisa® (Isatuximab-irfc) Prior Authorization Form

Member Name:	Date of Birth	h: Member ID#:	
Drug Information			
		Pharmacy billing (NDC:)	
Start Date (or date of next dose):	Dose:	Regimen:	
Billing Provider Information			
Provider NPI: Provider Name:			
Provider Phone: Provider Fax:			
Prescriber Information			
Prescriber NPI:	Prescriber Name:		
Prescriber Phone:	Prescriber Fax:	Specialty:	
<b>Criteria</b>			
<ul> <li>a. If yes, has the member failed i. If yes, did the prior thera Yes No</li> <li>3. Will isatuximab be used in combination a. If yes, has the member failed</li> <li>4. If diagnosis is NOT relapsed or remaining the prior therapsed or remaining the prior therapsed in the prior therapsed or remaining the prior the pr</li></ul>	ination with pomaliced at least 2 prior the pies include lenaliced ination with carfilzors 1 to 3 prior therape efractory multiple necessions.	idomide and dexamethasone? Yes No erapies? Yes No domide and a proteasome inhibitor? omib and dexamethasone? Yes No	
Prescriber Signature:  I certify that the indicated treatment.	dverse drug reactions:  is medically necess	ons related to isatuximab therapy?	

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy

Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

necessary. Failure to complete this form in full will result in processing delays.

**CONFIDENTIALITY NOTICE** 

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm - 147 1/6/2022